Sevgi Doğan
Sevgi Doğan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Gizem Gökçe Altaş
Etlik Şehir Hastanesi Çocuk Metabolizma Ana Bilim Dalı
4 shared publications - Mustafa Kılıç
Sağlık Bilimleri Üniversitesi Etlik Şehir Hastanesi Çocuk Metabolizma Ana Bilim Dalı
4 shared publications - Abdullah Sezer
Department of Medical Genetics, Ankara Etlik City Hospital, Ankara, Turkey
2 shared publications - Esra Sayar
Department of Pediatrics, Metabolism Unit Ankara Etlik City Hospital Ankara Turkey
2 shared publications - Suzan İcIl
Department of Pediatrics, Metabolism Unit Ankara Etlik City Hospital Ankara Turkey
2 shared publications - Abdullatif Bakır
Department of Medical Genetics, Ankara Etlik City Hospital, Ankara, Türkiye
1 shared publication
Latest Publications
- 3 September 2026
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 65 (3) , 596-602
İzole sülfit oksidaz eksikliği: SUOX geninde homozigot p.Gly362Ser varyantı saptanan 10 aylık bir olgu
İzole sülfit oksidaz eksikliği, SUOX genindeki bialelik patojenik varyantlara bağlı gelişen, ağır nörolojik tutulumla seyreden nadir bir nörometabolik hastalıktır. On aylık erkek hasta, mikrosefali, epilepsi, serebral palsi ve kardeş ölüm öyküsü nedeniyle metabolik açıdan değerlendirildi. Fizik muayenesinde gelişim geriliği, aksiyel hipotoni ve periferik spastisite saptandı. Beyin manyetik rezonans görüntülemesinde yaygın serebral atrofi, korpus kallozum agenezisi, ventrikülomegali ve periventriküler kistik değişiklikler izlendi. Klinik ekzom dizilemesinde SUOX geninde homozigot c.1084G>A (p.Gly362Ser) patojenik varyant gösterilerek izole sülfit oksidaz eksikliği tanısı doğrulandı. Ayrıca literatürde bildirilen Türk kökenli olgular klinik, radyolojik ve genetik özellikleri açısından gözden geçirildi. Erken başlangıçlı nöbetler, ilerleyici ensefalopati ve karakteristik nörogörüntüleme bulguları bulunan hastalarda izole sülfit oksidaz eksikliği ayırıcı tanıda düşünülmeli ve erken moleküler genetik inceleme yapılmalıdır.
- 3 September 2026
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 65 (3) , 596-602
İzole sülfit oksidaz eksikliği: SUOX geninde homozigot p.Gly362Ser varyantı saptanan 10 aylık bir olgu
İzole sülfit oksidaz eksikliği, SUOX genindeki bialelik patojenik varyantlara bağlı gelişen, ağır nörolojik tutulumla seyreden nadir bir nörometabolik hastalıktır. On aylık erkek hasta, mikrosefali, epilepsi, serebral palsi ve kardeş ölüm öyküsü nedeniyle metabolik açıdan değerlendirildi. Fizik muayenesinde gelişim geriliği, aksiyel hipotoni ve periferik spastisite saptandı. Beyin manyetik rezonans görüntülemesinde yaygın serebral atrofi, korpus kallozum agenezisi, ventrikülomegali ve periventriküler kistik değişiklikler izlendi. Klinik ekzom dizilemesinde SUOX geninde homozigot c.1084G>A (p.Gly362Ser) patojenik varyant gösterilerek izole sülfit oksidaz eksikliği tanısı doğrulandı. Ayrıca literatürde bildirilen Türk kökenli olgular klinik, radyolojik ve genetik özellikleri açısından gözden geçirildi. Erken başlangıçlı nöbetler, ilerleyici ensefalopati ve karakteristik nörogörüntüleme bulguları bulunan hastalarda izole sülfit oksidaz eksikliği ayırıcı tanıda düşünülmeli ve erken moleküler genetik inceleme yapılmalıdır.
- Open Access
- 4 March 2026
- Published by Akdeniz University in Akdeniz Medical Journal
- Vol. 12 (1)
Tüberoskleroz Kompleksi Tanılı Çocuk Hastalarda Everolimus Tedavisine İkincil Hiperlipidemi: Üç Olgunun Retrospektif Değerlendirmesi
Çocuklarda hiperlipidemi primer ve sekonder kaynaklı olabilir. Primer hiperlipidemi lipid ilişkili genetik nedenlere bağlı iken, sekonder hiperlipidemi altta yatan ikincil hastalıklara ve kullanılan ilaçlara bağlı olabilir. Tüberoskleroz tedavisinde kullanılan ve mTOR inhibitörü olan Everolimus, sekonder hiperlipidemiye neden olabilmektedir. Kliniğimize son iki yıl içerisinde konsülte edilen üç hastanın Everolimus tedavisi sürecindeki kan lipid değerleri geriye dönük olarak incelendi. Klinik ve biyokimyasal bulguları araştırıldı. Everolimus tedavisi alan her üç hastada sekonder hiperlipidemi gözlendi. Bir hastanın LDL kolesterol düzeyinde, bir hastanın trigliserid, bir hastanın ise hem LDL kolesterol, hem de trigliserid düzeylerinde yükselme oldu. Everolimus doz azaltımı ya da ara verilmesi ve yağdan kısıtlı diyet ile düzelme gözlendi. Bu durumda ilaç doz azaltımı, ara verilmesi ya da yağdan kısıtlı diyet ve antihiperlipidemik ilaçlar kullanılabilir. Primer hastalığın evresi ve plazma lipid düzeyleri tedavi kararında belirleyici rol oynar.
- 4 March 2026
- Published by Akdeniz University in Akdeniz Medical Journal
- Vol. 12 (1)
Open AccessTüberoskleroz Kompleksi Tanılı Çocuk Hastalarda Everolimus Tedavisine İkincil Hiperlipidemi: Üç Olgunun Retrospektif Değerlendirmesi
Çocuklarda hiperlipidemi primer ve sekonder kaynaklı olabilir. Primer hiperlipidemi lipid ilişkili genetik nedenlere bağlı iken, sekonder hiperlipidemi altta yatan ikincil hastalıklara ve kullanılan ilaçlara bağlı olabilir. Tüberoskleroz tedavisinde kullanılan ve mTOR inhibitörü olan Everolimus, sekonder hiperlipidemiye neden olabilmektedir. Kliniğimize son iki yıl içerisinde konsülte edilen üç hastanın Everolimus tedavisi sürecindeki kan lipid değerleri geriye dönük olarak incelendi. Klinik ve biyokimyasal bulguları araştırıldı. Everolimus tedavisi alan her üç hastada sekonder hiperlipidemi gözlendi. Bir hastanın LDL kolesterol düzeyinde, bir hastanın trigliserid, bir hastanın ise hem LDL kolesterol, hem de trigliserid düzeylerinde yükselme oldu. Everolimus doz azaltımı ya da ara verilmesi ve yağdan kısıtlı diyet ile düzelme gözlendi. Bu durumda ilaç doz azaltımı, ara verilmesi ya da yağdan kısıtlı diyet ve antihiperlipidemik ilaçlar kullanılabilir. Primer hastalığın evresi ve plazma lipid düzeyleri tedavi kararında belirleyici rol oynar.
- 3 February 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (7) , 681-689
A comparative analysis of all reported patients with MTHFS-related neurodevelopmental disorder
Objectives: 5,10-Methenyltetrahydrofolate synthetase (MTHFS) deficiency is an ultra-rare autosomal recessive inborn error of folate metabolism caused by biallelic pathogenic variants in the MTHFS gene and associated with a severe neurodevelopmental disorder. Methods: Patients with molecularly confirmed MTHFS deficiency were identified through a comprehensive search of the PubMed database. A total of 12 patients from 10 unrelated families, including our patient, were analyzed. Demographic data, clinical features, biochemical findings, neuroimaging and electrophysiological results, molecular genetic characteristics, treatment responses, and outcomes were systematically compared. Results: The disorder showed a pan-ethnic distribution. All patients presented with symptoms during the neonatal and/or infantile period. Clinical features included severe global developmental delay, microcephaly, hypotonia, growth retardation, mild dysmorphic features, and epilepsy. The male-to-female ratio was 1:1, and parental consanguinity was reported in 30 % of families. Laboratory findings revealed macrocytic anemia, hyperhomocysteinemia, and mildly reduced or low–normal cerebrospinal fluid 5-methyltetrahydrofolate levels. Brain magnetic resonance imaging demonstrated cerebral hypomyelination, thinning of the corpus callosum, cerebellar atrophy, vermian hypoplasia, and T2 hypointensity of the basal ganglia. Homozygous variants were identified in 60 % of patients, and missense variants accounted for 50 % of all detected variants. A total of 12 distinct pathogenic variants were reported, with c.434G>A p.(Arg145Gln) being the most recurrent (4/20 alleles, 20 %). Despite metabolic treatment, no significant clinical improvement was observed. Two patients (17 %) died at an early age, while the remaining patients exhibited severe neurodevelopmental impairment. Conclusions: MTHFS deficiency should be considered in the differential diagnosis of patients presenting with severe developmental delay and microcephaly accompanied by isolated hyperhomocysteinemia.
- 3 February 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (7) , 681-689
A comparative analysis of all reported patients with MTHFS-related neurodevelopmental disorder
Objectives: 5,10-Methenyltetrahydrofolate synthetase (MTHFS) deficiency is an ultra-rare autosomal recessive inborn error of folate metabolism caused by biallelic pathogenic variants in the MTHFS gene and associated with a severe neurodevelopmental disorder. Methods: Patients with molecularly confirmed MTHFS deficiency were identified through a comprehensive search of the PubMed database. A total of 12 patients from 10 unrelated families, including our patient, were analyzed. Demographic data, clinical features, biochemical findings, neuroimaging and electrophysiological results, molecular genetic characteristics, treatment responses, and outcomes were systematically compared. Results: The disorder showed a pan-ethnic distribution. All patients presented with symptoms during the neonatal and/or infantile period. Clinical features included severe global developmental delay, microcephaly, hypotonia, growth retardation, mild dysmorphic features, and epilepsy. The male-to-female ratio was 1:1, and parental consanguinity was reported in 30 % of families. Laboratory findings revealed macrocytic anemia, hyperhomocysteinemia, and mildly reduced or low–normal cerebrospinal fluid 5-methyltetrahydrofolate levels. Brain magnetic resonance imaging demonstrated cerebral hypomyelination, thinning of the corpus callosum, cerebellar atrophy, vermian hypoplasia, and T2 hypointensity of the basal ganglia. Homozygous variants were identified in 60 % of patients, and missense variants accounted for 50 % of all detected variants. A total of 12 distinct pathogenic variants were reported, with c.434G>A p.(Arg145Gln) being the most recurrent (4/20 alleles, 20 %). Despite metabolic treatment, no significant clinical improvement was observed. Two patients (17 %) died at an early age, while the remaining patients exhibited severe neurodevelopmental impairment. Conclusions: MTHFS deficiency should be considered in the differential diagnosis of patients presenting with severe developmental delay and microcephaly accompanied by isolated hyperhomocysteinemia.
- 6 March 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (7) , e64037
Expanding the Genetic Spectrum of PPM1K‐Related Maple Syrup Urine Disease: A Novel Mutation
Maple syrup urine disease (MSUD) is a rare inborn error of metabolism caused by impaired catabolism of branched‐chain amino acids (BCAAs). The genes BCKDHA, BCKDHB, DBT, and DLD encode the subunits of the branched‐chain α‐ketoacid dehydrogenase (BCKDH) complex, which is essential for BCAA metabolism. Catalytic subunits are BCKDHA, BCKDHB, DBT, and DLD, whereas the regulator subunits are PPM1K and BCKDK. PPM1K plays a critical role by dephosphorylating and activating this enzyme complex. Pathogenic variants in the PPM1K gene cause an extremely rare, mild form of MSUD. Here, we report an 8‐year‐old male patient with a mild form of MSUD putatively caused by a novel homozygous variant in PPM1K. The patient presented with mild dysmorphic features, delayed speech, relative microcephaly, and overweight, all considered familial phenotypic traits. Laboratory findings revealed mildly elevated plasma branched‐chain amino acids, mild lactic acidemia, and a slight increase in urinary keto acids. Exome sequencing identified a novel homozygous missense variant, c.925A>G p.(Ile309Val), in the PPM1K gene. This case represents the third reported patient with a mild form of MSUD associated with the first reported missense variant in the PPM1K gene in the literature, further expanding the clinical and genetic spectrum of PPM1K‐related disorders.
- 6 March 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (7) , e64037
Expanding the Genetic Spectrum of PPM1K‐Related Maple Syrup Urine Disease: A Novel Mutation
Maple syrup urine disease (MSUD) is a rare inborn error of metabolism caused by impaired catabolism of branched‐chain amino acids (BCAAs). The genes BCKDHA, BCKDHB, DBT, and DLD encode the subunits of the branched‐chain α‐ketoacid dehydrogenase (BCKDH) complex, which is essential for BCAA metabolism. Catalytic subunits are BCKDHA, BCKDHB, DBT, and DLD, whereas the regulator subunits are PPM1K and BCKDK. PPM1K plays a critical role by dephosphorylating and activating this enzyme complex. Pathogenic variants in the PPM1K gene cause an extremely rare, mild form of MSUD. Here, we report an 8‐year‐old male patient with a mild form of MSUD putatively caused by a novel homozygous variant in PPM1K. The patient presented with mild dysmorphic features, delayed speech, relative microcephaly, and overweight, all considered familial phenotypic traits. Laboratory findings revealed mildly elevated plasma branched‐chain amino acids, mild lactic acidemia, and a slight increase in urinary keto acids. Exome sequencing identified a novel homozygous missense variant, c.925A>G p.(Ile309Val), in the PPM1K gene. This case represents the third reported patient with a mild form of MSUD associated with the first reported missense variant in the PPM1K gene in the literature, further expanding the clinical and genetic spectrum of PPM1K‐related disorders.
- Open Access
- 5 September 2021
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 4 (5) , 752-757
Adolescent suicide: an overview
Suicide is the second leading cause of death among 15-19 year-olds globally. Recent years suicidal thoughts and attempts have increased in adolescents. While Turkey is among the countries with a low suicide rate, the last ten-year statistics show that suicide attempts have steadily increased especially among young people. The aim of this review is to determine the factors that cause suicide, the characteristics of suicide and to identify the necessary measures to prevent suicide in the adolescent period.
- 5 September 2021
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 4 (5) , 752-757
Open AccessAdolescent suicide: an overview
Suicide is the second leading cause of death among 15-19 year-olds globally. Recent years suicidal thoughts and attempts have increased in adolescents. While Turkey is among the countries with a low suicide rate, the last ten-year statistics show that suicide attempts have steadily increased especially among young people. The aim of this review is to determine the factors that cause suicide, the characteristics of suicide and to identify the necessary measures to prevent suicide in the adolescent period.